Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAG Adagene	$1.92 -3.5%	$1.92	$1.33 ▼ $3.58	$90.45M	0.74	91,863 shs	9,972 shs
ADAP Adaptimmune Therapeutics	$0.08 -0.5%	$0.25	$0.08 ▼ $1.35	$21.18M	2.18	14.17 million shs	83.23 million shs
AYTU Aytu BioPharma	$2.40 -1.6%	$2.16	$0.95 ▼ $2.85	$21.54M	0.13	147,409 shs	86,793 shs
IVVD Invivyd	$0.73 +5.5%	$0.79	$0.35 ▼ $2.74	$87.85M	0.51	639,784 shs	822,841 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAG Adagene	0.00%	-3.52%	+1.86%	+24.19%	-21.31%
ADAP Adaptimmune Therapeutics	0.00%	-76.97%	-68.17%	-72.05%	-93.99%
AYTU Aytu BioPharma	0.00%	-8.75%	-1.03%	+83.22%	-9.43%
IVVD Invivyd	0.00%	-6.71%	-2.75%	+16.53%	-41.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAG Adagene	2.5114 of 5 stars	3.3	5.0	0.0	0.0	1.7	0.0
ADAP Adaptimmune Therapeutics	2.4819 of 5 stars	4.0	4.0	0.0	1.3	0.8	0.0
AYTU Aytu BioPharma	3.1649 of 5 stars	3.5	2.0	3.4	0.6	0.0	0.6
IVVD Invivyd	2.9923 of 5 stars	3.6	4.0	0.0	0.6	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAG Adagene	2.50	Moderate Buy	$8.00	316.67% Upside
ADAP Adaptimmune Therapeutics	2.00	Hold	$1.35	1,591.70% Upside
AYTU Aytu BioPharma	3.00	Buy	$10.00	316.67% Upside
IVVD Invivyd	3.25	Buy	$5.85	698.85% Upside

Current Analyst Ratings Breakdown

Latest AYTU, IVVD, ADAG, and ADAP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/29/2025	ADAP Adaptimmune Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/29/2025	ADAP Adaptimmune Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
7/1/2025	AYTU Aytu BioPharma	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
6/30/2025	AYTU Aytu BioPharma	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/26/2025	ADAP Adaptimmune Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$1.50 ➝ $0.50
6/26/2025	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/26/2025	IVVD Invivyd	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
5/28/2025	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $5.00
5/16/2025	IVVD Invivyd	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
5/14/2025	ADAP Adaptimmune Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$1.50 ➝ $1.00
5/14/2025	ADAP Adaptimmune Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$1.00 ➝ $0.46

(Data available from 8/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAG Adagene	$100K	904.51	N/A	N/A	$1.14 per share	1.68
ADAP Adaptimmune Therapeutics	$178.03M	0.12	N/A	N/A	$0.05 per share	1.60
AYTU Aytu BioPharma	$81M	0.27	N/A	N/A	$4.64 per share	0.52
IVVD Invivyd	$25.38M	3.46	N/A	N/A	$0.56 per share	1.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAG Adagene	-$33.42M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
ADAP Adaptimmune Therapeutics	-$70.81M	-$0.27	N/A	N/A	N/A	-38.91%	-163.73%	-23.65%	8/11/2025 (Estimated)
AYTU Aytu BioPharma	-$15.84M	-$0.72	N/A	∞	N/A	2.37%	3.51%	0.91%	9/25/2025 (Estimated)
IVVD Invivyd	-$169.93M	-$1.20	N/A	6.66	N/A	-389.01%	-165.24%	-99.71%	8/13/2025 (Estimated)

Latest AYTU, IVVD, ADAG, and ADAP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	IVVD Invivyd	-$0.04	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	ADAP Adaptimmune Therapeutics	-$0.11	N/A	N/A	N/A	$11.04 million	N/A
5/15/2025	Q1 2025	IVVD Invivyd	-$0.04	-$0.14	-$0.10	-$0.14	$34.45 million	$11.30 million
5/14/2025	Q3 2025	AYTU Aytu BioPharma	-$0.17	$0.20	+$0.37	$0.21	$13.74 million	$18.45 million
5/13/2025	Q1 2025	ADAP Adaptimmune Therapeutics	-$0.18	-$0.18	N/A	-$0.18	$6.55 million	$7.29 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAG Adagene	N/A	N/A	N/A	N/A	N/A
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
AYTU Aytu BioPharma	N/A	N/A	N/A	N/A	N/A
IVVD Invivyd	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAG Adagene	0.01	2.30	2.30
ADAP Adaptimmune Therapeutics	4.24	2.02	1.79
AYTU Aytu BioPharma	0.27	1.03	0.87
IVVD Invivyd	N/A	1.53	1.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAG Adagene	9.51%
ADAP Adaptimmune Therapeutics	31.37%
AYTU Aytu BioPharma	33.49%
IVVD Invivyd	70.36%

Insider Ownership

Company	Insider Ownership
ADAG Adagene	21.20%
ADAP Adaptimmune Therapeutics	12.74%
AYTU Aytu BioPharma	3.60%
IVVD Invivyd	25.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAG Adagene	260	47.11 million	37.12 million	Not Optionable
ADAP Adaptimmune Therapeutics	490	265.05 million	231.28 million	Optionable
AYTU Aytu BioPharma	160	8.98 million	8.65 million	Not Optionable
IVVD Invivyd	100	119.96 million	89.49 million	Optionable

AYTU, IVVD, ADAG, and ADAP Headlines

Recent News About These Companies

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for ...

July 23, 2025 | bakersfield.comB

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome

July 23, 2025 | globenewswire.com

National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population

July 21, 2025 | globenewswire.com

Invivyd (NASDAQ:IVVD) Trading Up 5.1% - Here's Why

July 18, 2025 | marketbeat.com

Invivyd, Inc. (IVVD) stock price, news, quote & history - Yahoo Finance

July 8, 2025 | nz.finance.yahoo.com

Invivyd, Inc. Forms SPEAR Study Group to Investigate PEMGARDA® Therapy for Long COVID and Post-Vaccination Syndrome

July 2, 2025 | quiverquant.comQ

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

July 2, 2025 | globenewswire.com

Invivyd, Inc. Announces Promising Phase 1/2 Data for VYD2311 Monoclonal Antibody Candidate in COVID-19 Prevention and Treatment

June 26, 2025 | quiverquant.comQ

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

June 26, 2025 | globenewswire.com

H.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue Shortfall

May 29, 2025 | msn.com

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus

May 27, 2025 | globenewswire.com

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network®

May 23, 2025 | bakersfield.comB

Invivyd, Inc. Announces Inclusion of PEMGARDA® in NCCN Clinical Practice Guidelines for B-Cell Lymphomas

May 23, 2025 | quiverquant.comQ

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

May 23, 2025 | globenewswire.com

Invivyd Commends FDA on New Framework for COVID-19 Vaccines Amidst Uncertainty Regarding Booster Efficacy

May 23, 2025 | nasdaq.com

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

May 21, 2025 | globenewswire.com

Earnings call transcript: Invivyd Q1 2025 sees stock drop amid earnings miss

May 16, 2025 | investing.com

Invivyd, Inc. (NASDAQ:IVVD) Q1 2025 Earnings Call Transcript

May 16, 2025 | insidermonkey.com

Invivyd Inc (IVVD) Q1 2025 Earnings Call Highlights: Strategic Shifts and Financial Discipline ...

May 16, 2025 | finance.yahoo.com

Invivyd Reports Q1 2025 Financial Results and Outlook

May 15, 2025 | tipranks.com

INVIVYD Earnings Preview: Recent $IVVD Insider Trading, Hedge Fund Activity, and More

May 15, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AYTU, IVVD, ADAG, and ADAP Company Descriptions

Adagene NASDAQ:ADAG

$1.92 -0.07 (-3.52%)

Closing price 08/1/2025 03:55 PM Eastern

Extended Trading

$1.93 +0.01 (+0.52%)

As of 08/1/2025 04:04 PM Eastern

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Adaptimmune Therapeutics NASDAQ:ADAP

$0.08 0.00 (-0.50%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$0.08 0.00 (-0.38%)

As of 08/1/2025 07:59 PM Eastern

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Aytu BioPharma NASDAQ:AYTU

$2.40 -0.04 (-1.64%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.40 0.00 (-0.21%)

As of 08/1/2025 07:37 PM Eastern

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Invivyd NASDAQ:IVVD

$0.73 +0.04 (+5.52%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$0.74 +0.00 (+0.51%)

As of 08/1/2025 07:32 PM Eastern

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time